Delix Raises $100m Series C for Non-Hallucinatory Depression Pill

Delix Therapeutics has raised $100m in a new funding round led by Johnson & Johnson’s venture arm and co-led by the SV Health Investors-managed Dementia Discovery Fund, with proceeds targeting zalsupindole, its oral non-hallucinatory neuroplasticity therapy for depression. Reported on 10 November 2026, the round signals a substantial recalibration of investor conviction in psychedelic-derived drug development, moving commercial focus toward non-hallucinatory, at-home oral formulations and away from classic clinic-supervised psychedelic workflows.

Zalsupindole is an oral pill intended for at-home use, designed to deliver antidepressant effect through neuroplasticity, the brain’s process of rewiring its connections, while avoiding the hallucinations and clinic-supervised dosing associated with classic psychedelic therapeutics. An initial study of 18 patients showed depression scores dropping by roughly half, with the benefit lasting four weeks after the last dose, though the data remain preliminary and are being prepared for journal submission. A 240-person study is planned to start in the first half of 2027, with data expected in the first half of 2028. The round drew more investor demand than Delix could fill, bringing the company’s lifetime funding to $215m. CEO Mark Rus positioned the capital raise around an investor environment where interest in the space has never been higher. Delix has flagged a potential IPO as soon as next year, depending on markets and clinical progress.

The commercial opportunity rests on a substantial addressable depression market where current standard-of-care SSRIs, SNRIs and tricyclics remain effective only in a subset of patients, and where J&J’s own Spravato (ketamine-based nasal spray) has built a multibillion-dollar franchise under medical supervision. An at-home oral non-hallucinatory depression therapy would materially expand treatment accessibility, remove the supervised dosing economics constraint and open substantially larger prescription volume opportunity. Grand View Research projects psychedelic medicines could reach $11.7bn by 2033. Delix’s broader pipeline also covers substance use, schizophrenia and neurodegenerative disorders including Alzheimer’s and Parkinson’s, with the Dementia Discovery Fund co-lead signalling investor conviction in the neuroplasticity mechanism beyond mood disorders.

The commercial signal is a maturing psychedelic-derived therapeutics category where non-hallucinatory oral formulations are opening fundamentally different commercial economics against supervised-dose incumbents. Phase 2 data readout and potential IPO are the key near-term catalysts. Expect sustained investor interest in neuroplasticity-based depression therapeutics and continued venture capital flow into the psychedelic-derived drug development category through 2027 and 2028.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Bailey Osborne today!